TECVAYLI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECVAYLI (TECVAYLI).
Bispecific T-cell engager antibody that binds to BCMA on multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and targeted cytotoxicity.
| Metabolism | Metabolized via catabolism into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Primarily catabolized to small peptides and amino acids; not expected to be excreted renally or hepatically to a significant extent. |
| Half-life | 22.5 days (range 10–35 days) based on population pharmacokinetic analysis; supports every-2-week dosing after step-up. |
| Protein binding | Negligible; no specific binding proteins identified—expected to be in low μM range, not saturable. |
| Volume of Distribution | 5.8 L (central volume); interpatient variability 35%; not weight-normalized; indicates limited extravascular distribution. |
| Bioavailability | Not applicable (administered subcutaneously); SC absorption 100% relative to IV reference from population PK. |
| Onset of Action | First response observed as early as 0.9 months; median time to first response 1.3 months (range 0.9–9.5 months) with recommended dosing. |
| Duration of Action | Median duration of response 14.8 months (95% CI: 9.5–not estimable); continuous treatment until progression or unacceptable toxicity. |
Subcutaneous injection: Step-up dosing schedule. First dose 0.06 mg/kg, then 0.3 mg/kg on day 4, followed by 1.5 mg/kg weekly starting day 7. Maximum single dose 1.5 mg/kg.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). Insufficient data for severe renal impairment or dialysis. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Insufficient data for moderate (Child-Pugh B) or severe (Child-Pugh C) impairment. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended based on age, but monitor for increased toxicity due to age-related renal or hepatic decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECVAYLI (TECVAYLI).
| Breastfeeding | It is unknown whether TECVAYLI is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, women should discontinue breastfeeding during treatment and for 5 months after the last dose. No M/P ratio is available. |
| Teratogenic Risk | Based on its mechanism of action (bispecific T-cell engager targeting BCMA and CD3), TECVAYLI may cause fetal harm. Cytokine release syndrome and immune-mediated effects could potentially affect pregnancy. Due to insufficient human data, it is advised to avoid use during pregnancy unless the benefit outweighs the risk. In animal studies, no reproductive toxicity studies are available. The drug should be used with effective contraception during treatment and for 5 months after the last dose. |
■ FDA Black Box Warning
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
| Serious Effects |
["None"]
| Precautions | ["Cytokine release syndrome (CRS)","Neurologic toxicity including ICANS","Infections","Cytopenias","Hepatotoxicity","Embryo-fetal toxicity"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of cytokine release syndrome, neurological toxicities, and infections. Consider fetal monitoring with ultrasound in pregnant patients. Assess for potential immune-mediated effects on the fetus. |
| Fertility Effects | No studies on fertility have been conducted with TECVAYLI. Based on its mechanism of action (T-cell activation and potential immune-mediated effects), it may affect reproductive function in both males and females. Advise patients of potential impact on fertility. |